Mitochondrial Stack
AKA Energy stack · Mito stack
Last reviewed 2026-10-30
Our read Opinion
Longevity-crowd favorite.
Claims made by sellers, clinics and users. Not verified.
Better cellular energy, endurance and 'mitochondrial aging' support.
Combines three different mitochondrial angles: MOTS-c (metabolic signaling), SS-31 (stabilizes the mitochondrial membrane) and NAD+ (energy coenzyme).
Evidence level: Animal studies mostly
No published human trials of this combination. SS-31 (elamipretide) has human data only in rare mitochondrial disease.
No human trials have tested this combination. Combining compounds can also combine unknown side effects and interactions.
SS-31 is FDA approved only for Barth syndrome; MOTS-c is compoundable alone under the HHS policy; NAD+ is a supplement/compounded product.
Statuses change; check the linked primary sources.
Each piece has an interesting mechanism. 'Stacking mechanisms' is not the same as stacking evidence.
| Field | MOTS-c | Elamipretide | NAD+ |
|---|---|---|---|
| Type | Research Only | FDA Approved | Research Only |
| Regulatory status | Not FDA-approved; no verified marketing authorization | FDA accelerated approval (Forzinity, 2025) | No FDA-approved NAD+ wellness therapy identified |
| Compounding status | Off Category 2, review pending | Approved product (not applicable) | Compounded by pharmacies (verify) |
| FDA-approved indications | None | Improvement of muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg (accelerated approval). | None |
| Categories | Longevity & mitochondrial | Longevity & mitochondrial | Longevity & mitochondrial |
| Claimed uses |
|
|
|
| Mechanism | Mitochondrial-derived peptide linked to metabolic stress signaling and AMPK activation. Animal studies suggest effects on insulin sensitivity; endogenous biomarker associations do not establish treatment efficacy. | Mitochondria-targeting tetrapeptide that binds cardiolipin in the inner mitochondrial membrane to support mitochondrial structure and function. | NAD+ is an electron carrier in energy metabolism and a substrate for enzymes including sirtuins and PARPs. Its essential physiological role does not establish benefit from administering additional NAD+. |
| Evidence level | Animal studies mostly | Small/early human studies | Small/early human studies |
| Evidence / Hype (opinion) | Evidence Hype | Evidence Hype | Evidence Hype |
| Momentum (opinion) | Rising | Watch | Rising |
| Routes | — | — | — |
| WADA | Prohibited | Verify | Verify |
| Where it stands (opinion) | FDA lists MOTS-c among withdrawn nominations, not as authorized for compounding. Trials of analogues should not be treated as proof for native MOTS-c; WADA 2026 S4.4.1 prohibits it. | Now an FDA-approved rare-disease medicine, not simply an unapproved research peptide. Approval rests on an intermediate muscle-strength endpoint; broad anti-aging benefits are not established. | Small human metabolism studies and a registered comparative trial exist, without established anti-aging efficacy. FDA reports adverse reactions to compounded injectables consistent with endotoxin contamination. |
| Last reviewed | 2026-10-30 | 2026-10-30 | 2026-10-30 |
| News (30d) | 0 | 0 | 0 |
No news yet for these peptides.
Information only. Not medical advice. Describing a stack is not a recommendation to combine, obtain or use any compound. Ratings and "Our Take" are editorial opinion. Full disclaimer.